key: cord-0010116-2ynsyoks authors: Hart, Stefan W.; Nolte, Ingo title: Hemostatic Disorders in Feline Immunodeficiency Virus‐Seropositive Cats date: 2008-06-28 journal: J Vet Intern Med DOI: 10.1111/j.1939-1676.1994.tb03250.x sha: 87776ce51c1b3a94ef70e518f906cdd1f761388f doc_id: 10116 cord_uid: 2ynsyoks The hemostatic function of 40 feline immunodeficiency virus (FlV) seropositive and 8 FIV and feline leukemia virus (FeLV) seropositive cats was evaluated and compared with reference values from 30 clinically healthy cats. The FIVpositive cats were divided into 3 groups: group I included asymptomatic carriers; group II comprised sick FIV‐infected cats with illnesses not likely to influence the hemostatic system; and group III included FIV‐positive cats with diseases potentially associated with coagulopathies. Platelet counts in FIV/FeLV‐infected cats were significantly lower than in healthy cats (P < .003), whereas the differences in the 3 groups of FIV‐positive cats were variable (group I, P= .009; II, P= .05; III, P= .09). Thrombocytopenia (< 145,000 platelets/μL) was present in 4 FIV‐positive and 3 FIV/FeLV‐positive cats. Platelet aggregation induced by collagen (0.5 and 0.25 μg/mL), adenosine diphosphate (ADP) (1 and 0.6 μmol/L), and thrombin (0.4 and 0.25 IU/mL) was not significantly different from that of healthy cats. The plasma coagulation system was evaluated by measuring one‐stage prothrombin time (OSPT), activated partial thromboplastin time (APTT), thrombin time, fibrinogen concentration, coagulation factor assays, fibrinogen and fibrin degradation products (FDP), and plasma exchange test. The OSPT was similar in FlV‐seropositive cats and in the healthy control group. Cats with FIV infection, however, had markedly shorter clotting times than healthy cats when using a modified test system (P < .05). In all groups of FIV‐infected cats and in those with FIV/FeLV infection, APTT measured with 2 different commercially available tests, and a modified plasma assay was markedly prolonged compared with healthy cats (APTT1 and 2:3 modification: P < .01; APTT2: P < .05 except group III). In 22 of 40 cats with FIV and in 5 of 8 cats with FIV/FeLV infection, plasma samples were beyond the reference range. The thrombin time was also significantly prolonged in cats with FIV and FIV/FeLV infection (P < .01); values in 17 of 40 FIV‐positive cats were above reference range. The mean fibrinogen concentration of cats with FIV and FIV/FeLV infection was higher than in the healthy control group (P < .001). Factor VIII activity of 4 cats with FIV infection was 1.5 times higher than that of healthy cats. Factor XII activity of 3 cats from a group of 20 cats with prolonged APTT was between 20% and 35%. Factor IX and XI activities ranged between 70% and 120%. The markedly prolonged APTT in 2 FIV‐positive cats could be shortened considerably in a plasma exchange test using 20% feline pooled plasma. The alterations in the coagulogram of FIV‐seropositive cats were not related to a clinical stage or concurrent diseases. A definite explanation of the distinct disorder within the intrinsic plasma coagulation system in FIV‐infected cats was not found. 0.25 IU/mL) was not significantly different from that of healthy cats. The plasma coagulation system was evaluated by measuring one-stage prothrombin time (OSPT), activated partial thromboplastin time (APTT), thrombin time, fibrinogen concentration, coagulation factor assays, fibrinogen and fibrin degradation products (FDP), and plasma exchange test. The OSPT was similar in FIV-seropositive cats and in the healthy control group. Cats with FIV infection, however, had markedly shorter clotting times than healthy cats when using a modified test system emostatic disorders can occur in the course of different H viral infections in cats.'-6 Disseminated intravascular coagulation (DIC) is a complication of feline infectious peritonitis virus (FIPV) and feline panleucopenia virus infections. Feline leukemia virus (FeLV) infection can cause thrombocytopenia, and seldom thrombocythemia. ss6 After the discovery of the feline immunodeficiency virus (FIV) in 1987, its virologic features, pathogenesis, and clinical and pathological behavior have been well d e~c r i b e d .~-~~ Reports on hemostatic disorders associated with FIV infection are rare; moderate thrombocytopenia during the disease was identified in some FIV-positive ~a t s ?~-~~ The purpose of this study was to characterize the primary and secondary hemostatic abnormalities in FIV-infected cats. Cats were considered healthy based on a normal physical examination, a hemogram within the reference range, and a negative enzyme linked immunosorbent assay (ELISA) for FIV and FeLV. Healthy cats were presented to the clinic for vaccination or neutering. Blood was collected from the jugular or cephalic vein from 30 healthy cats, 40 FIV-positive cats and 8 cats with concurrent FIV and FeLV infection. Table 1 lists age, breed, and gender of the cats evaluated. A small aliquot of blood (0.5 mL) was collected in a tube containing edetic acid (EDTA) for platelet counting and hemogram. The remainder of the sample (6 mL) was added to a tube containing 3.8% sodium citrate (blood/anticoagulant = 10: 1) for aggregation studies and coagulation assays. (P < .05). In all groups of FIV-infected cats and in those with FIV/FeLV infection, APTT measured with 2 different commercially available tests, and a modified plasma assay was markedly prolonged compared with healthy cats (APTTI and 2:3 modification: P < .01; APTTP: P < .05 except group Ill). In 22 of 40 cats with FIV and in 5 of 8 cats with FIV/FeLV infection, plasma samples were beyond the reference range. The thrombin time was also significantly prolonged in cats with FIV and FIV/FeLV infection (P < .Ol); values in 17 of 40 FIV-positive cats were above reference range. The mean fibrinogen concentration of cats with FIV and FIV/FeLV infection was higher than in the healthy control group (P < .OOl). Factor Vlll activity of 4 cats with FIV infection was 1.5 times higher than that of healthy cats. Factor XI1 activity of 3 cats from a group of 20 cats with prolonged APTT was between 20% and 35%. Factor IX and XI activities ranged between 70% and 120%. The markedly prolonged APTT in 2 FIV-positive cats could be shortened considerably in a plasma exchange test using 20% feline pooled plasma. The alterations in the coagulogram of FIVseropositive cats were not related to a clinical stage or concurrent diseases. A definite explanation of the distinct disorder within the intrinsic plasma coagulation system in FIV-infected cats was not found. FIV and FeLV serology was performed using a commercially available ELISA test (Cite Combo, IDEXX Laboratories, Westbrook, ME). Cats with less intense color development in the ELISA were either tested repeatedly (twice in an interval of 2 months), or the diagnosis was confirmed by western blot!' The FIV-and FeLVseropositive cats were client-owned patients of the Clinic of Small Animals, and were thus in different stages of infection ( Table 2) . FIV-positive cats were divided in three groups: group I included asymptomatic cats, Group I1 comprised FIV-seropositive cats with illnesses not likely to induce hemostatic abnormalities (eg, gingivitis, diarrhea, skin disease), and group I11 included FIV-infected cats with concurrent diseases that may be associated with coagulopathies (uremia, liver disease, neoplasia, etc). Platelet-rich plasma (PRP) for platelet aggregation was obtained by centrifuging citrated blood at 80g and 20°C in a centrifuge (Beckman GPKR, Beckman Instruments, Munich) for 10 minutes. Centrifugation for 15 minutes at 2500g resulted in platelet-poor plasma (PPP). PRP was diluted with PPP to a platelet number of 300,00O/pL. In case of a lower platelet count, undiluted PRP was used for platelet aggregation. Until testing, aliquots of frozen PPP were stored at -70°C. HART AND NOLTE After incubation in a water bath for 30 minutes at 37"C, the glass tube for quantification of fibrinogen and fibrin degradation products (FDP) was centrifuged at 15OOg for 10 minutes, and the serum was stored at -70°C until further testing. A 20-pL capillary tube was filled with EDTA-anticoagulated blood and placed in a Thrombo plus (Sarstedt, Numbrecht, Germany) tube after 2 minutes; the platelets were then counted in a hemacytometer within 3 hours of sample collection. Platelet aggregation studies were performed with an Automated Platelet Aggregation and Coagulation Tracer (APACT) (Labor, Ahrensburg, Germany) within 3 hours of venipuncture. PRP was adjusted to 100% light transmission and PPP to 10% transmission. PRP (200 pL) was incubated for 30 seconds at 37°C and then aggregation was started by adding 10 pL of an agonist. The following agonists were used: collagen (0.25 and 0.5 pg/mL; Kollagenreagens Horm, Hormon-Chemie, Munich, Germany), Adenosinediphosphate (ADP) (0.6 pmol/L; 1 fimol/L; Sigma Diagnostics, St. Louis, MO) and thrombin (0.25 and 0.4 IU/mL; Test-Thrombin, Behringwerke, Marburg, Germany). One Germany) and compared with a standard curve of pooled plasma from 10 healthy cats. Serum was serially diluted from 1: I to 154 with glycine buffer. Ten-microliter aliquots of diluted serum and latex suspension were gently mixed on a test card and evaluated for agglutination 2 minutes later. The highest dilution with clear agglutination was considered as the agglutination titer. Citrated plasma (0.2 mL) from FIV-infected cats with highly prolonged APTT were replaced by 0.04,0.10, and 0.16 mL of pooled plasma of healthy cats and the APTT determined. Sfatistical Analysis. The nonparametrical Kruskal-Wallis analysis of variance was used to compare the platelet count and the coagulogram (screening tests, fibrinogen) of 3 groups of RVseropositive cats, FeLV/FIV-infected cats, and healthy controls." Tables 3 and 4 summarize the results of the coagulograms and platelet counts in clinically healthy, FIV-and FIV/ FeLV-infected cats. Platelet counts in FIV/FeLV-positive cats were lower than in the control group (P = .003), whereas in the FIVseropositive cats (group I, P = .09; 11, P = .05; 111, P = .09) they were variable. Thrombocytopenia without evidence of spontaneous bleeding was present in 4 FIV-infected (10%; 2 upper respiratory signs, 1 neoplasia, 1 dermatitis) and 3 FIV/FeLV-infected cats (37.5; liver disease, dermatitis and fever). Platelet aggregation could be induced in healthy and FIVpositive cats by the same agonists. The mean maximal aggregation and aggregation gradients were similar in FIV-infected cats and in healthy ones ( Table 5) . The OSPTs were not significantly different in healthy and FIV-positive cats with the 2 tests evaluated (OSPTI, 2). The modified OSPTl differed in FIV-seropositive cats from the control depending on the dilution (1:3 dilution: group I, P = .05, 11, P = .006, 111, P = .05; 1:4 dilution: group I, P = .023; 11, P = .002; 111, P = .007). The APTT was significantly prolonged in all groups of FIV-infected cats (APTTI group I, P = .007; 11, P = .001; 111, P = .004; 2:3 dilution: group I, P = .006; 11, P = .003; 111, P = .005) and in FIV/FeLV-seropositive cats (APTTI P = .001,2:3 dilution P = .007) ( Table 4 ). The APTTl values were beyond the reference range in 22 FIV-positive cats. Five plasma samples of FIV/FeLV seropositive cats were also beyond the reference range for APTT 1. With the second APTT test, significant differences from the control group were observed in groups I (P = .004), I1 (P = .020), and in FIV/FeLV-infected cats (P = .029). The TT was also prolonged in FIV-(group I, P = .008; 11, P = ,001; 111, P = .002), and FIV/FeLV-positive cats (P = .042) when compared with the healthy controls (Tables 3 and 4 ). Fibrinogen concentration was elevated over reference range in 27 FIV-seropositive (67.5%) and 5 FIV/FeLV-seropositive cats (62.5%), so that the results remarkably differed from those of the healthy ones (P < .OO 1) (Tables 3 and 4) . Seventeen FIV-infected (42.5%) and 4 FIV/FeLV-infected cats (50%) had fibrinogen concentrations above 400 mg/dL. The results of the platelet counts and the hemostasis screening tests did not vary considerably among the 3 groups of FIV-infected cats, and the cause of the underlying disease did not seem to have an influence on the hemostatic system (Table 4) . Coagulation factor assays (factors VIII, IX, XI, and XII) were performed in 20 FIV-seropositive cats with prolonged APTT (APTTI: mean t SD = 44.3 t 30.9 s; APTTl 2:3 dilution: mean +-SD = 53.9 * 27.9 s; APTT2: mean 4 SD = 17.5 k 9.8 s; TT: mean t SD = 19.2 It-4.7 s). Factor VIII activity was higher than 150% in 4 of 20 FIV-infected cats (mean factor VIII activity in all FIV-seropositive cats: 123%). Mean factor XI1 activity was 84%; 3 FIV-positive cats had 20 to 35% factor XI1 activity. Factor IX and XI activity in 10 FIV-positive cats ranged between 70% and 120%. The highest agglutination titer of fibrinogen and fibrin degradation products in 10 FIV-positive cats with prolonged APTT was 1 : 16 (reference range below 1 :8). A plasma exchange test performed in 2 cats with prolonged APTT resulted in a clear shortening of the coagulation time (APTTI) after adding 20% feline pooled plasma. Addition of more pooled plasma led to a successive normalization of the coagulation time. Plasma exchange after incubation for 1 hour yielded similar results. Reports on coagulation disorders during the course of FIV infection in cats are rare, probably because hemorrhagic diatheses occur infrequently. Only Grindem et all4 briefly described bleeding disorders in FIV-seropositive cats. An FIV-positive cat with leukopenia and thrombocytopenia associated with gastrointestinal bleeding was described by Friend et al.39 Published reference ranges for platelet counts in normal cats are ~a r i a b l e .~~-~' The reference range in our study in 30 healthy cats (145,000 to 569,00O/pL) is similar to those reported by other^.^^,^^ However, other investigators have reported ranges of 300,000 to 800,000 p l a t e l e t~/ p L .~~-~~ Thrombocytopenia plays an important role in various infectious and also occurs in cats with FIV infect i~n .~' ,~~ In our study, 4 of 40 FIV-seropositive cats (10%) were thrombocytopenic (< I45,000/pL). According to Shel- itive asymptomatic cats. itive cats with diseases not influencing the hemostatic system. itive cats with illnesses potentially associated with coagulopathies. -Reagenz), undiluted plasma. ton et a13' the prevalence of thrombocytopenia in FIV-positive cats is 6%. A mild thrombocytopenia (>100,000 and < 150,000 platelets/pL) was found by other investigators in 16% of FIV-infected cats.37 A third report only mentioned one thrombocytopenic cat among 46 FIV-seropositive cats.29 In only one cat, thrombocytopenia was associated with a spontaneous bleeding disorder.39 Thrombocytopenia appears to be more frequent in cats with concurrent FIV and FeLV infection (1 1%),38 probably because FIV/FeLV-positive cats have a 77-fold increase in the risk for developing myeloproliferative diseases,26 which in turn results in thrombocytopenia due to myelophthisis. In our study, 3 of 8 FIV/FeLV-seropositive cats (37.5%) were thrombocytopenic. In addition to platelet count, platelet function is vital for primary hemostasis. Platelets from clinically healthy cats aggregate well after adding collagen, ADP, arachidonic acid, or thrombin, but they do not respond to ristocetin, kaolin, or e~i n e p h r i n e .~~-'~ Thrombocytopathies occur in the course of various feline diseases, such as liver disease, leukemia, and Chkdiak-Higashi ~yndrome.~'-'~ However, in our study platelet aggregation in FIV-seropositive cats did not differ from that of healthy cats. The OSPT evaluates the extrinsic and common pathways of the plasma coagulation system. The results of our study reveal that the reference ranges for the 2 tests (OSPTI and 2) we used to measure OSPT clearly differ. It has been shown that an 80% plasma dilution leads to significant prolongation of the OSPT, ' ' 4 In an earlier study in our laboratory, plasma diluted with DBA buffer to 1:3 and 1:4 led to a smoother standard curve and improved the readability of the assay in healthy cats.6' An alteration in the extrinsic pathway of the coagulation system in FIV-positive cats was detected by the modified OSPTl test. However, the unmodified OSPTI test yielded similar results in FIV-infected and healthy cats. Unfortunately, a definite explanation for these discrepancies is not possible with the diagnostic tests currently available for the cat. The published reference ranges for the APTT vary considerably when using the same test system but different de-vi~es.4~~~' Gentry and Cooper6' evaluated 4 reagents and found remarkable differences. However, the authors regarded all of the reagents tested as useful in the diagnosis of severe coagulation disorders.60 Both reagents evaluated in our study resulted in different reference ranges ( 14 to 20 seconds for APTT I and 1 1 to 14 seconds for APTT2). The use of plasma dilutions is recommended when evaluating the APTT in cats.44 To improve sensitivity compared with undiluted plasma in healthy cats, the plasma sample in our study only needed to be diluted in a ratio of 2 3 for APTTI. In vitro alterations in the intrinsic coagulation system were detected in 55% of FIV-infected cats in our study. They were characterized by a prolongation of the APTT, which was similar for both test reagents (APTTI, 2) and for the modified test assay of APTT 1, which is more sensitive than APTT2. However, dilution did not provide additional benefit when evaluating the APTT. The TT evaluates the generation of fibrin from fibrinogen after the addition of thrombin. It is influenced by heparin, FDPs, and severe dysfibrinogenemia or hypofibrinogenemia.2'4,62 The reference ranges for the TT vary considerably, depending on the thrombin concentration used. Our reference ranges were similar to those published in the liter-The fibrinogen concentration quantified using the method of C l a~s s~~~~~,~'~~~ yielded reference ranges of 54 to 282 mg/mL. This reference range is similar to that published by other authors (50 to 310 mg/dL).47,65 Hyperfibrinogenemia has not been previously reported in FIV-and FIV/FeLV-seropositive cats. Yet, this is common in cats with inflammatory d i~e a s e s .~~~~"~ Because the Clauss method only detects functional, clottable fibrinogen, it is unlikely that dysfibrinogenemia accounted for the prolonged TT." Isolated prolongation of the APTT may be caused by a clotting factor deficiency in the intrinsic pathway. Deficiencies of factors VIII, IX, XI, and XI1 have been reported in Cats.63,64,7 1-82 Hemophilia A (factor VIII deficiency) is associated with a marked prolongation of the APTT." However, in this study F VIII activity was elevated (> 120%) in 13 of the 20 FIV-positive cats (65%) in which it was evaluated. This is likely a reflection of the fact that F VIII is an acute phase reactant, and its plasma activity increases in the course of inflammatory proce~ses.'~ Factor IX deficiency (hemophilia B) is also associated with a prolongation of the APTT in the cat," but a particularly marked prolongation of this screening test occurs in combined factors IX and XI1 deficiencies (> 100 s).".'~ Factor IX-activity of the FIV-seropositive cats evaluated was within the reference ranges and did not cause the abnormality in the hemostatic system. Previous reports suggest that F XI1 deficiency is relatively common in healthy However, in most of these, F XI1 activity is below 5%. Therefore, the F XI1 activity of 20% and 30% in 3 FIV-positive cats in this study is not likely to explain the prolongation of the APTT. Circulating FDPs appear to be common in cats with DIC.2,4 High concentrations of circulating FDPs (> 100 pg/ dL) may cause prolongation of the APTT in human^.'^^^^ It is unlikely that the concentration of FDPs in FIV-infected cats in this study was a consequence of DIC. Moreover, these concentrations were probably not high enough to effect the APTT.42. 45 A plasma exchange test was performed in 2 FIV-seropositive cats with markedly prolonged APTT to elucidate this coagulation disorder. In humans, circulating inhibitors of coagulation occur in various disease^.^^-^' Progressive inhibitory antibodies that exert an effect after 1 to 4 hours of plasma incubation are distinguished from direct inhibiting agents with immediate action.86 They can inhibit single coagulation factors (eg, F VIII or IX) or cause prolongations of the APTT or OSPT. The antibodies, usually immunoglobulin (1g)G or IgM, interfere with phospholipids involved in the coagulation process. However, despite the prolonged clotting times, spontaneous bleeding occurs only when concurrent thrombocytopenia or factor deficiency exist.89 There is only one report of a coagulation disorder induced by circulating inhibitors to F XI in a cat.74 Mixing of normal pooled plasma with the patient's plasma (with and without incubation for 1 hour) resulted in a slow normalization of the APTT, and gradual increases of F XI activity. From these results, the authors concluded that an inhibitory immunoglobulin may have been pre~ent.'~ In our study, the result of the plasma exchange test revealed that already a 20% to 50% mixture of patients with feline pool plasma corrects the prolonged APTT. Therefore, the presence of inhibiting antibodies is relatively unlikely. Based on the reports in the literature and on our own results, there is no satisfying explanation for the abnormalities in the intrinsic pathway of the plasma coagulation system in FIV-infected cats. Thrombozytopenie bei Feliner Infektioser Panleukopenie Disseminated intravascular coagulation in experimentally induced infectious peritonitis Evaluation of antithrombin-Ill activity as a coindicator of disseminated intravascular coagulation in cats with induced feline infectious peritonitis virus infection Feline leukemia virus induced thrombocytopenia and macrothrombocytosis in cats Isolation ofa T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome Feline immunodeficiency virus infection Pathogenesis of experimentally induced feline immunodeficiency virus infection in cats 0. Prevalence of feline leukaemia virus and antibodies to feline immunodeficiency virus in cats in the United Kingdom Prevalence ofantibody to feline immunodeficiency virus in some cat populations Epizootologicassociation between feline immunodeficiency virus infection and fe line leukemia virus seropositivity Feline immunodepressive retrovirus infections in France Existence of feline immunodeficiency virus infection in Japanese cat population since 1968 Felines T-lymphotropes Lentivirus (FTLV): Experimentelle Infektion und Vorkommen in einigen Landern Europas Serologische Untersuchungen zum Vorkommen des felinen Immundefizienzvirus (FIV) bei Katzen in Osterreich Erste Ergebnisse uhr die Verbreitung FIV-(FI'LV-)seropositiver Katzen in Deutschland und Interpretation der Ergebnisse Epidemiologic observations on feline immunodeficiency virus and toxoplasma gondii coinfection in cats in Baltimore, Md. J Am Vet Med A m 23 Prevalence of feline immunodeficiency virus and feline leukemia virus infedons in pet cats Feline immune Feline leukemia virus infection as a potentiating cofactor for the primary and secondary stages of experimentally induced feline immunodeficiency virus infection Clinical staging of feline immunodeficiency virus infection Clinical and laboratory findings in cats infected with feline immunodeficiency virus Feline immunodeficiency virus FIV(FTLV)-lnfektion der Katze: 1 I Falle-Beitrag zur Epidemiologie, klinischen Symptomatologie und zum Krankheitsverlauf Das Feline Immunschwache Virus in der Schweiz: Klinik und Epidemiologie im Vergleich mit dem Leukamie-und dem Coronavirus Feline immunodeficiency virus, a model for reverse transcriptase-targeted chemotherapy for acquired immune deficiency syndrome Suppression offeline immunodeficiency virus infection in vivo by 9-(2-phosphonometh-0xyethyl)adenine Epidemiological and clinical aspects of feline immunodeficiency virus infection in cats from the continental United States and Canada and possible mode of transmission Feline immunodeficiency virus: prevalence, disease associations and isolation Screening coagulation tests in the cat: Reference values based on direct venipucture and catheterized samples Coagulation, fibrinolysis, and kinin generation in adult cats Platelet concentration and platelet volume distribution in healthy cats Current Veterinary Therapy X. Small Animal Practice Effects of aspirin and propranolol alone and in combination on hemostatic determinants in the healthy cat Effects of apirin and propranolol on feline platelet aggregation Platelet aggregation in feline cardiomyopathy A comparative study of platelet aggregation in man and laboratory animals Platelet aggregation and platelet nucleotide concentration in different species Aggregation ofcat platelets in vitro Zur Thrombozytenaggregation der Katze Platelet disorders in the dog and cat. Part I: Physiology and pathogenesis Hereditary and acquired thrombopathias Current Veterinary Therapy Prolonged bleeding time of Chediak-Higashi cats corrected by platelet transfusion Reagent dependent variability of plasma clotting times in the cat Schwierigkeiten bei der Gerinnungsdiagnostik der Katze Activated partial thromboplastin time and activated coagulation time in monitoring heparinized cats Comparative hematology: Studies on cats including one with factor XI1 (Hageman) deficiency Acquired hemostatic problems in a cat with factor XI1 deficiency Schalm OW. Plasma protein: Fibrinogen ratios in routine clinical material from cats, dogs, horses, and cattle-Part 111 Feline infectious peritonitis: something old, something new The value of a single haematological examination in the diagnosis of disease in the cat lation studies in various animal species The inheritance pattern of factor XI1 (Hageman) deficiency in domestic cats Hemorrhage in a cat caused by inhibition of factor XI (plasma thromboplastin antecedent) Haemophilia A (factor VIII deficiency) in the cat A bleeding disorder (von Willebrand's disease) in a Himalayan cat Factor IX deficiency (Hemophilia B) in two male domestic Short-Hair cats Combined factors IX and XI1 deficiencies in a family ofcats Kitchens CS. Concept of hypercoagulability: A review ofits development, clinical application and recent progress Consumptive Thrombohemorrhagic Disorders Zuverlassigkeit des Fibrinogen-(Fibrin-)Spaltproduktnachweises im Plasma mit Thrombinkoagulase-, Reptilase-und Thrombin-Gerinnungszeit Acquired inhibitors in nonhemophilic patients A clinical study of the lupus anticoagulant A survey of 215 nonhemophilic patients with inhibitors to factor VIII